Table 1.

Estimated dietary intake of acrylamide and EOC cases in the EPIC subcohort of women by country

CountryCohort samplePerson-yearsAcrylamide, μg/dAcrylamidea, μg/dAcrylamide, μg/kg body weight/dEOC casesInvasive EOC cases by histologic subtype
SerousMucinousEndometrioidClear cellNOSOthers
Median (QR)Median (QR)Median (QR)n (%)n (%)n (%)n (%)n (%)n (%)n (%)
France65,538680,30519.2 (14.3–25.2)17.7 (14.0–21.9)0.3 (0.2–0.4)159 (13.4)97 (16.7)15 (19.0)14 (11.9)2 (3.9)9 (3.6)6 (37.5)
Italy29,277327,6429.7 (6.5–13.8)8.6 (5.4–11.8)0.2 (0.1–0.2)104 (8.7)56 (9.6)8 (10.1)14 (11.9)3 (5.9)15 (6.0)1 (6.3)
Spain23,508283,56218.4 (11.9–26.9)19.5 (14.1–26.2)0.3 (0.2–0.4)68 (5.7)32 (5.5)3 (3.8)10 (8.5)5 (9.8)6 (2.4)2 (12.5)
United Kingdom50,858567,69730.6 (22.4–40.9)31.2 (24.2–39.7)0.5 (0.3–0.7)211 (17.7)73 (12.5)11 (13.9)15 (12.7)14 (27.5)74 (29.7)4 (25.0)
The Netherlands26,074306,43629.1 (21.3–38.4)29.7 (23.1–38.0)0.4 (0.3–0.6)105 (8.8)55 (9.5)6 (7.6)10 (8.5)4 (7.8)20 (8.0)
Greece14,376140,15717.6 (12.9–23.4)18.9 (15.3–23.1)0.3 (0.2–0.3)37 (3.1)12 (2.1)1 (1.3)3 (2.5)2 (3.9)17 (6.8)1 (6.3)
Germany26,571264,22622.4 (16.9–29.6)23.6 (19.1–29.7)0.3 (0.2–0.4)82 (6.9)53 (9.1)7 (8.9)8 (6.8)9 (3.6)
Sweden26,375349,30820.6 (15.8–26.9)22.6 (18.7–27.0)0.3 (0.2–0.4)137 (11.5)50 (8.6)14 (17.7)10 (8.5)8 (15.7)53 (21.3)2 (12.5)
Denmark27,403302,43334.5 (27.5–42.3)34.7 (28.4–41.5)0.5 (0.4–0.6)140 (11.8)76 (13.1)8 (10.1)18 (15.3)8 (15.7)30 (12.0)
Norway35,026340,87617.4 (13.6–21.5)20.2 (16.8–23.7)0.3 (0.2–0.3)148 (12.4)78 (13.4)6 (7.6)16 (13.6)5 (9.8)16 (6.4)
Total325,0063,562,64221.3 (14.7–30.4)21.9 (16.0–29.8)0.3 (0.2–0.5)1,191582791185124916

Abbreviations: NOS, not otherwise specified; QR, quartile range (25th–75th percentile).

  • aEnergy-adjusted using the residual method.